VCV. N. Charushin

V. N. Charushin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


V. N. Charushin has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 January 2015
      • Vol. 78  (2) , 34-8

    [Experimental comparative pharmacokinetics of levofloxacin, triazavirin, and related conjugate].

    by I V Blazhennikova, A F Kurliakova, V N Bykov, D S Geĭbo, A S Nikiforov, A V Stepanov, V N Charushin, O N Chupakhin, S K Kotovskaia, V L Rusinov

    A comparative study of the pharmacokinetics of levofloxacin and triazavirine as well as 2-methylthio-6-nitro-1,2,4-triazolo[5,1-ñ]-1,2,4-triazine-7(4Í)-ide (3S)-(-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-d,e]-1,4-benzoxazine-6-carboxylic acid (conjugate 2) obtained by conjugation of triazavirine and levofloxacin, representing a new class of pharmacological agents, was carried out in experiments on rats. It is established that conjugate 2 in comparison to individual levofloxacin and triazavirine has a higher relative bioavailability and lower rate of elimination, which can lead to improved effectiveness of therapy at reduced dose and frequency of drug administration.


    • 13 March 2013
      • Vol. 57  (6) , 9-12

    [A new antiviral drug Triazavirin: results of phase II clinical trial].

    by O I Kiselev, E G Deeva, T I Mel'Nikova, K N Kozeletskaia, A S Kiselev, V L Rusinov, V N Charushin, O N Chupakhin

    The results of the clinical trial testing the efficacy of a new anti-influenza drug Triazavirin are presented in this work. The data of the trial were gathered during the 2010 influenza season. The treatment with oral Triazavirin significantly reduced the duration of the main clinical symptoms of influenza (intoxication, fever, respiratory symptoms), decreased the incidence of the influenza-related complications and the use of symptomatic drugs. The re-isolation rate of the influenza A and B viruses was significantly lower in the patients who were using Triazavirin. The analysis of the clinical data showed that the optimal prescribed dosage was 250 mg 3 times a day.


    • 1 January 2011
      • Vol. 56, 10-2

    [Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1)].

    by S Ia Loginova, S V Borisevich, V A Maksimov, V P Bondarev, S K Kotovskaia, V L Rusinov, V N Charushin, O N Chupakhin

    Therapeutic activity of Triazavirin against experimental influenza A was studied on albino mice intranazally infected with influenza virus A/Chicken/Kurgan/Russia/02/05 (H5N1) vs. reference drugs (Oseltamivir, Remantadin and Arbidol). The study showed that in a therapeutic dose of 1 mg/kg Triazavirin was efficient in protection of the animals from death. Its protective therapeutic efficacy (36.7+/-1.7%) was close to that of Oseltamivir (50.0+/-0.0%), comparable with that of Remantadin (38.3+/-1.7%) and higher than that of Arbidol (11.7+/-1.7%). During the whole observation period (up to the terminal phase) Triazavirin inhibited the influenza virus A accumulation in the lungs of the infected albino mice by more than 3 lg.


    • 1 January 2010
      • Vol. 55, 25-8

    [Triazavirin prophylactic efficacy against influenza virus A (H5N1)].

    by S Ia Loginova, S V Borisevich, V A Maksimov, V P Bondarev, S K Kotovskaia, V L Rusinov, V N Charushin, O N Chupakhin

    The experimental study of the prophylactic efficacy of Triazaverin against the experimental form of the influenza virus A (H5N1) on albino mice intranasally infected with the influenza virus A/Chicken/Kurgan/Russia/02/05 vs. the reference drugs Tamiflu, Remantadin and Arbidol showed that in doses of 1 to 100 mg/kg it was efficient in the animal protection from death. The drug was also efficient in the urgent prophylaxis. Triazaverin effectively inhibited the influenza A virus multiplication in the lungs of the albino mice.


    • 1 January 1992
      • Vol. 326  (2) , 376-9

    [Anti-HIV activity of complex isoborneol ethers].

    by A G Pokrovskiĭ, O A Pliasunova, L S Sandakhchiev, O I Kiselev, O N Chupakhin, V N Charushin, M G Ponizovskiĭ, G Ia Dubur, E A Bisenieks